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LSD1 activation promotes inducible 
EMT programs and modulates the 
tumour microenvironment in breast 
cancer
T. Boulding1, R. D. McCuaig1, A. Tan1, K. Hardy1, F. Wu1, J. Dunn1, M. Kalimutho2,  
C. R. Sutton1, J. K. Forwood3, A. G. Bert4, G. J. Goodall4, L. Malik5,6, D. Yip5,6, J. E. Dahlstrom7,  
A. Zafar1, K. K. Khanna2 & S. Rao1
Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying 
epigenetic control is poorly understood. Lysine-specific demethylase 1 (LSD1) is a key histone 
demethylase that alters the epigenetic landscape. Here we explored the role of LSD1 in global 
epigenetic regulation of EMT, cancer stem cells (CSCs), the tumour microenvironment, and therapeutic 
resistance in breast cancer. LSD1 induced pan-genomic gene expression in networks implicated in EMT 
and selectively elicits gene expression programs in CSCs whilst repressing non-CSC programs. LSD1 
phosphorylation at serine-111 (LSD1-s111p) by chromatin anchored protein kinase C-theta (PKC-θ), is 
critical for its demethylase and EMT promoting activity and LSD1-s111p is enriched in chemoresistant 
cells in vivo. LSD1 couples to PKC-θ on the mesenchymal gene epigenetic template promotes LSD1-
mediated gene induction. In vivo, chemotherapy reduced tumour volume, and when combined with an 
LSD1 inhibitor, abrogated the mesenchymal signature and promoted an innate, M1 macrophage-like 
tumouricidal immune response. Circulating tumour cells (CTCs) from metastatic breast cancer (MBC) 
patients were enriched with LSD1 and pharmacological blockade of LSD1 suppressed the mesenchymal 
and stem-like signature in these patient-derived CTCs. Overall, LSD1 inhibition may serve as a 
promising epigenetic adjuvant therapy to subvert its pleiotropic roles in breast cancer progression and 
treatment resistance.
Epithelial-to-mesenchymal transition (EMT) is a plastic cellular process in which fully differentiated epithelial 
cells reversibly dedifferentiate into cells with mesenchymal characteristics1. EMT is physiological in embryonic 
development and wound healing2 but pathological in cancer, where it endows cells with highly aggressive traits 
that facilitate dissemination, therapeutic resistance, and relapse3. EMT results in cytoskeletal restructuring, 
loss of cell-cell adhesion, and abnormal apical-basal polarity, thereby increasing motility and invasion of the 
cancer cells1,2. EMT also induces the formation of cancer stem cells (CSCs) with tumourigenic and metastatic 
capabilities4 that, although only constituting a small proportion of the main tumour bulk, possess the capac-
ity to self-renew and differentiate5 and enhance resistance to chemotherapy, ionizing radiation, and hormone 
therapies6.
EMT is regulated by extensive modifications to the histone template and many hallmark changes during EMT 
are dependent on these alterations7,8. Histone methylation was originally thought to be fixed, but the discov-
ery of the first histone demethylase, lysine-specific demethylase 1 (LSD1), highlighted that this modification 
was dynamic9. LSD1 is a chromatin-modifying enzyme that selectively catalyzes the removal of mono- and 
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dimethylated groups from H3K4 and H3K9 depending on its association with nuclear receptors10,11. H3K4 meth-
ylation is generally associated with gene activation and H3K9 methylation with gene repression, so LSD1 acts as 
a dual transcriptional activator and repressor depending on its target residue12.
LSD1 is implicated in the pathogenesis of various epithelial cancers in the prostate, bladder, liver, non-small 
cell lung cancer (NSCLC), and neuroblastomas13–18. In breast cancer, LSD1 expression increases with progression 
from ductal carcinomas in situ (DCIS) to invasive ductal carcinoma19 and overexpression is positively correlated 
with estrogen receptor negative (ER−) status20. Knockdown or inhibition of LSD1 reduces both the invasiveness 
and proliferative capacity of breast cancer cells in vitro21,22.
LSD1 is implicated in the regulation of EMT. Specifically, LSD1 mediates global EMT-related epigenetic 
reprogramming in mouse hepatocytes, thereby facilitating cell migration and chemoresistance23, and LSD1 
promotes EMT, migration, and proliferation in NSCLC and hepatocellular carcinoma16,18. Several physiologi-
cal events occur during EMT including loss of the epithelial transmembrane protein E-cadherin (encoded by 
CDH1)24 mediated by EMT-inducing transcription factors (EMT-TFs) including Snail, Slug and Zinc finger 
E-box-binding homeobox 1 (ZEB1)25,26. In breast cancer, Snail recruits LSD1 to epithelial gene promoters includ-
ing that of CDH1, where LSD1 mediates H3K4me2 demethylation and consequent transcriptional silencing27,28. 
Additionally, LSD1 can interact with Slug to promote migration and invasion of breast cancer cell lines29,30. Recent 
studies have implicated LSD1 in breast CSC self-renewal31. However, the global epigenetic effects of LSD1 in 
breast cancer cells, the tumour microenvironment, and therapeutic resistance are unknown.
Somatic mutations in tumour can result in dysregulation of an inflammatory response and induce a 
pro-tumour environment32. Notably, recent studies have suggested that tumour-associated stroma also builds a 
supportive environment for tumour cell proliferation, invasion, dissemination and immune evasion33. Tumour 
stroma comprises heterogeneous collection of cells, amongst this cancer-associated fibroblasts (CAFs), mac-
rophages and myeloid-derived cells promote tumourigenesis through paracrine mechanisms in particular 
through the secretion of cytokines and growth factors34. Moreover, CAFs have emerged as important participants 
in cancer progression and are implicated in regulating CSC self-renewal in the tumour niche35. CAF induction can 
be characterised by an increase in fibroblast activation protein (FAP) as well as CAF-induced cytokine CCL235,36.
Here we evaluated the role of LSD1 in the global epigenetic regulation of EMT, CSCs, and therapeutic resist-
ance in breast cancer. We show that LSD1 regulates several breast cancer programs, namely EMT, CSC formation 
and tumour progression. Pharmacological inhibition of LSD1 in combination with existing chemotherapy regi-
mens effectively reduces chemotherapy-induced EMT, and CAF burden whilst promoting innate M1 macrophage 
infiltration at the primary tumour site. Inhibition of LSD1 in CTCs isolated from patients with MBC successfully 
reduces the mesenchymal and stem-like burden of these cells. Thus, LSD1 is an exemplar epigenetic target in 
breast cancer.
Results
LSD1 is induced during EMT and regulates key EMT markers. To understand how LSD1 functions in 
EMT, epithelial MCF-7 cells were treated with the well-established EMT-inducers phorbol-12-myristate-13-ace-
tate (PMA) and transforming growth factor-β (TGF-β)4,37,38, which potentiate EMT in MCF-7 cells when admin-
istered in combination38. EMT was confirmed by the hallmark loss of E-cadherin and induction of vimentin and 
Snail (Supplementary Fig. 1a,b), as well as phenotypic morphological changes as early as 2 hours after treatment 
with PMA + TGF-β (Supplementary Fig. 1c). LSD1 expression peaked at 36 hours and then returned to baseline 
after 60 hours of treatment with PMA + TGF-β, and, after PMA + TGF-β withdrawal at 60 hours, LSD1 expression 
decreased before returning to near basal levels indicating that LSD1 induction is reversible (Fig. 1a). Moreover, 
the spatiotemporal induction pattern of LSD1 was largely consistent with that observed for the key EMT-TF, 
Snail from as early as 24 hours during both PMA + TGF-β-treatment and after PMA + TGF-β withdrawal 
(Supplementary Fig. 1d). At the protein level immunofluorescence microscopy revealed a significant increase 
in LSD1 total nuclear fluorescence intensity (TNFI) following induction of EMT in MCF-7/PMA + TGF-β cells 
and in fully dedifferentiated mesenchymal MDA-MB-231 cells (Fig. 1b). Additionally, induction of EMT was 
observed in both T47D and ZR751 cells after PMA + TGF-β (Supplementary Fig. 1e), which was accompanied 
by an induction of LSD1 at the protein level (Supplementary Fig. 1f). Given that LSD1 has previously been shown 
to interact with Snail in vitro28, we examined their relationship and whether it differed in the mesenchymal state. 
Using the Pearson’s correlation co-efficient (PCC) of Snail and LSD1 as a measure of colocalization, we found a 
significant increase in their colocalization in MCF-7/PMA + TGF-β cells (PCC = 0.170) and MDA-MB-231 cells 
(PCC = 0.380) (Fig. 1c).
As these data indicate that LSD1 is induced during EMT, we were interested in examining LSD1 expression 
after inducing the opposing biological process, mesenchymal-to-epithelial transition (MET). To do so, mesenchy-
mal MDA-MB-231, MDA-MB-436 and SUM149 PT cells were treated with erlotinib, which has previously been 
identified as a MET-inducer. MET was identified in each cell line by a dose-dependent increase in E-cadherin, 
and reduction in vimentin, Snail and ZEB1 (Supplementary Fig. 2a). Interestingly, we observed a dose-dependent 
reduction in LSD1 protein levels after MET induction in all cell lines (Supplementary Fig. 2b). Moreover, MET 
was induced in MDA-MB-231 cells using either compound 27 (C27), a specific PKC-θ inhibitor, or bisindolylma-
leimide I (BIM), a pan-PKC inhibitor (Supplementary Fig. 2c). Again, we observed a reduction in LSD1 protein 
levels after MET induction (Supplementary Fig. 2d). Collectively, these results suggest that LSD1 expression is 
proportional to the mesenchymal status of breast cancer cells.
Since LSD1 may, therefore, regulate downstream events during EMT, we examined several key EMT markers 
after treatment with pargyline (an LSD1 and its monoamine oxidase activity inhibitor39) or a previously validated 
pool of three specific 19–25-nucleotide LSD1 small interfering RNAs (siRNAs) targeting LSD1 (knockdown 
confirmed by microscopy and qPCR; Supplementary Fig. 3). LSD1 inhibition increased E-cadherin total cell 
fluorescence intensity (TCFI) and decreased Snail TNFI and vimentin TCFI in MCF-7, MCF-7/PMA + TGF-β, 
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and MDA-MB-231 cells (Fig. 1d). Similar results were observed after siRNA-mediated knockdown of LSD1 in 
MCF-7, MCF-7/PMA + TGF-β and MDA-MB-231 cells (Fig. 1e). To further explore the role of LSD1 during 
EMT, we examined LSD1 activity based on its demethylation of H3K4 residues. LSD1 activity was 45% lower in 
MDA-MB-231 cells than MCF-7 cells (Fig. 1f), suggesting that LSD1 is more repressive in luminal type epithelial 
MCF-7 cells than basal type mesenchymal MDA-MB-231 cells. Collectively, as reported previously, LSD1 modu-
lates breast cancer EMT, colocalises with the key EMT-TF Snail, and regulates the expression of several hallmark 
EMT proteins including E-cadherin and vimentin. Notably, we report here reduced repressive activity of LSD1 
in mesenchymal cells.
LSD1 tethers to chromatin and regulates primary and secondary genome-wide programs that 
activate EMT-related pathways. To further elucidate LSD1’s contribution to breast cancer EMT, we per-
formed RNA expression profiling using Affymetrix microarrays on MCF-7 cells transfected with either LSD1 or 
mock siRNAs after PMA + TGF-β treatment. Of the 3502 probes upregulated during EMT, 1459 (41.7%) were 
reversible on LSD1 siRNA knockdown and, of the 3351 probes downregulated during EMT, 790 (23.6%) were 
reversible (Fig. 2a). The induced LSD1-sensitive genes were enriched for EMT-related processes including cell 
migration, cell motility, response to wounding, cell differentiation, and cell adhesion (Fig. 2b).
To help determine which LSD1-sensitive genes were direct LSD1 targets, we performed Chromatin 
immunoprecipitation-sequencing (ChIP-seq) on MCF-7 and MCF-7/PMA + TGF-β cells. Considerably more 
LSD1 binding regions (6487) were detected in PMA + TGF-β cells. LSD1 largely occupied intergenic and intronic 
regions in MCF-7 and MCF-7/PMA + TGF-β cells, and there was a substantial increase in the proportion of LSD1 
bound to regions annotated as promoters during EMT (Fig. 2c). Utilizing information on the chromatin state and 
CCCTC-binding factor (CTCF) binding in these regions in MCF-7 cells40, we found that a large proportion of the 
MCF-7/PMA + TGF-β regions were marked as active promoters (as defined by H3K4me3 and H3K27ac) (Fig. 2d).
Figure 1. LSD1 is induced in mesenchymal cells and promotes breast cancer EMT markers. (a) LSD1 transcript 
levels measured by qPCR in MCF-7 cells after incubation with PMA + TGF-β or withdrawal of PMA+TGF-β 
after 60 h incubation at the indicated time points. Data are expressed as fold change relative to 0 h stimulation or 
0 h stimulation withdrawal (n = 3). *Indicates significance relative to 0 h stimulation. (b) Immunofluorescence 
microscopy was performed on cells fixed and probed with primary anti-LSD1 or anti-Snail antibodies and 
DAPI. Representative images for each dataset are shown. Graph represents the TNFI values for LSD1 measured 
using ImageJ to select the nucleus minus background (n > 50 individual cells). (c) The PCC was determined 
for LSD1 and Snail (n = 40 individual cells). −1 = inverse of colocalization; 0 = no colocalization; +1 = perfect 
colocalization. TCFI of E-cadherin and vimentin and TNFI of Snail and in MCF-7, MCF-7/PMA+ TGF-β and 
MDA-MB-231 cells after treatment with either (d) mock and LSD1 siRNA; or (e) vehicle alone and pargyline 
(n ≥ 30 individual cells). (f) LSD1 H3K4 demethylation activity assay was performed on MCF-7, MCF-7/
PMA+ TGF-β, and MDA-MB-231 nuclear extracts in triplicate wells. LSD1 demethylase activity was calculated 
and graph depicts percentage of activity relative to MCF-7 cells (n = 2). All data represents the mean ±SE. Scale 
bars = 10 µm. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, Mann-Whitney test.
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Figure 2. LSD1 selectively targets gene induction programs promoting EMT and CSCs. (a) Induced and 
repressed probes following treatment with either mock or LSD1 siRNA in MCF-7/PMA+ TGF-β cells. Probes 
with a log2 (0.5)-fold difference were considered induced or repressed. (b) Induced LSD1-sensitive genes were 
profiled for enrichment of biological processes and KEGG pathways. The significance of the enrichment of each 
group is indicated, hypergeometric test. LSD1 ChIP-seq peaks were annotated to: (c) summarised chromatin 
environments of the nearest Ensembl transcript. Peaks were classified as rRNA, 5′UTR, promoter (<1 kb from 
TSS), intergenic, intron, exon, pseudo, TTS, ncRNA, or 3′UTR; and (d) summarised CTCF/chromatin states 
in MCF-7 cells. (e) LSD1 ChIP-seq peaks were grouped by indicated distance to the nearest TSS of induced or 
repressed genes based on their sensitivity to LSD1 siRNA in MCF-7 and MCF-7/PMA+ TGF-β cells. Graphs 
represent the percentage of genes that lie within each group. (f) Venn diagram depicting the separation of 
LSD1 ChIP-seq peaks in MCF-7/PMA+ TGF-β cells. (g) Induced LSD1-sensitive genes with GO or KEGG 
annotations in indicated pathways. Genes within the circle are direct LSD1 targets, outside the circle are 
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We overlaid our MCF-7 and MCF-7/PMA + TGF-β gene expression sets with LSD1 ChIP-seq data to deter-
mine if LSD1 preferentially tethered to induced or repressed genes, and within what distance of the TSSs of differ-
entially expressed genes. After EMT induction, LSD1 occupied a higher proportion of regions within all distances 
of an induced gene transcription start site (TSS) than a repressed gene TSS (Fig. 2e). Furthermore, a greater 
proportion of the LSD1-sensitive induced genes had LSD1 binding than repressed genes (Fig. 2e). However, only 
around 17% of genes induced during EMT had chromatin-tethered LSD1 within 10 kb of the TSS. DNA looping 
enables distant binding of factors, and up to 39% of the LSD1-sensitive induced genes had LSD1 binding within 
100 kb. It is, therefore, likely that a large proportion of LSD1-sensitive genes are induced due to indirect effects 
of LSD1. As a conservative approach, we classified those genes with LSD1-sensitive gene expression and LSD1 
binding within 5 kb of their TSS as direct LSD1 targets and those without as indirect (Fig. 2f).
We next analyzed all directly and indirectly targeted LSD1-sensitive genes and classified them according to 
EMT-related pathways. Several genes in each group were both direct and indirect LSD1 targets, indicating a broad 
role for this enzyme in promoting EMT (Fig. 2g). The ratio of indirect to direct LSD1 targets was slightly lower for 
TF and forkhead box (FOX) proteins compared to other groups, suggesting that LSD1 may preferentially target 
TFs to achieve its secondary effects. Indeed, our recent study41 on the regulation of DNA accessibility in MCF-7/
PMA cells identified an important role for AP-1 family members such as JUN, JUNB, and FOS, which are direct 
LSD1 targets (Fig. 2g). Therefore, LSD1 executes genome-wide EMT programs through both direct and indirect 
actions, the latter most likely via its target TFs.
LSD1 selectively targets CSCs during EMT. Given that EMT is known to induce CSC formation, we 
next investigated whether LSD1 regulates breast CSCs. We overlaid LSD1 ChIP-seq and expression data with 
our previously published38 expression profiles generated from CSCs and non-CSCs (NCSCs) to explore the role 
of LSD1 in CSC regulation. A significantly higher proportion of LSD1-bound regions in MCF-7/PMA + TGF-β 
cells lay closer to genes induced in CSCs compared to NCSCs (Fig. 2h). We next intersected the LSD1 siRNA 
expression profiles with the CSC and NCSC expression profiles to determine any differential expression of 
these genes between the two cell subsets. A significantly (p = 1.3 × 10−9) greater proportion of the induced 
LSD1-sensitive genes had higher expression in CSCs than NCSCs compared to the inducible LSD1-insensitive 
genes. Furthermore, the repressed LSD1-sensitive genes had significantly (p < 2.2 × 10−16) biased expression 
toward NCSCs compared to the repressed LSD1-insensitive genes (Fig. 2i).
To validate any phenotypic correlations in vitro, we next examined the CD44+/CD24− breast CSC composi-
tion in MCF-7, MCF-7/PMA + TGF-β and MDA-MB-231 cells. Treatment with LSD1 siRNA nearly completely 
abrogated CD44+/CD24− CSC formation after PMA + TGF-β-induced EMT in MCF-7 cells, whilst pargyline 
was partially inhibitory (Fig. 2j). These results are consistent with previous reports implicating LSD1 in breast 
CSC regulation31. However, in MDA-MB-231 cells with a high constitutive CSC population42, LSD1 knockdown 
had no effect on their maintenance whilst LSD1 inhibition promoted their formation (Fig. 2k). These differences 
between MCF-7/PMA + TGF-β cells and MDA-MB-231 cells are likely to be in part due to differential roles for 
LSD1 in the formation compared to the maintenance, of breast CSCs. Nevertheless, our data indicates that LSD1 
selectively targets and promotes breast CSCs by regulating inducible gene expression programs whilst acting as 
a repressor of NCSCs.
PKC-θ directly phosphorylates LSD1 at serine-111 and regulates its repressive activity and 
nuclear localization. We have recently shown that protein kinase C-theta (PKC-θ) directly regulates induc-
ible gene expression signatures during breast cancer EMT and in CSCs38, and our studies have shown that PKC-θ 
tethers to the chromatin template in complex with LSD1 to express inducible immunological response genes in 
T-cells43. We initially questioned whether LSD1 and PKC-θ co-exist during EMT and in dedifferentiated mesen-
chymal cells. Double staining and immunofluorescence microscopy showed that LSD1 and PKC-θ do not colocal-
ise in epithelial MCF-7 cells. However, upon EMT, LSD1 and PKC-θ display moderate colocalization in MCF-7/
PMA + TGF-β cells (PCC = 0.278) and high colocalization in fully dedifferentiated mesenchymal MDA-MB-231 
cells (PCC = 0.519) (Fig. 3a).
Given that PKC-θ and LSD1 colocalise during EMT and in the mesenchymal state, we explored whether PKC-θ 
directly phosphorylates LSD1 using an array-based in vitro kinase assay. Of 201 overlapping peptide constructs, 
15 were positive for phosphorylation events (top 10 shown in Supplementary Fig. 4). Sequence analysis of these 
15 peptides showed that three peptides including the top two hits, were localised to the nuclear localisation signal 
(NLS) region (highlighted in red; Supplementary Fig. 4b). The peptide with the strongest phosphorylation signal 
(peptide 1) was focused on serine-111 (highlighted in blue) near the NLS domain. Since this phosphorylation 
site is directly adjacent to the NLS, it is likely that serine-111 is accessible and amenable to phosphorylation, as 
functional NLS domains are externalised and allow interaction with nuclear import receptors. A model of the full 
length LSD1 protein was generated by Phyre244 highlighting the accessibility of serine-111 and the close proxim-
ity of the highly-positively charged NLS domain (Fig. 3c). A serine/threonine-specific motif for PKC-θ-mediated 
indirect LSD1 targets. (h) LSD1 ChIP-seq-peaks were annotated by indicated distance to the nearest TSS of 
CSC > NCSC or NCSC > CSC transcripts in MCF-7/PMA+ TGF-β cells. Graphs represent the percentage of 
genes that lie within each group. Fisher’s exact t test was performed comparing CSCs vs NCSCs and p values 
are shown for indicated distances. (i) Percent of genes that are LSD1 sensitive or LSD1 insensitive and either 
expressed CSC > NCSC or NCSC > CSC. Percentage CD44+/CD24− cells as measured by flow cytometry after 
treatment with vehicle alone, pargyline, mock siRNA or LSD1 siRNA in (j) MCF-7 and MCF-7/PMA+ TGF-β; 
or (k) MDA-MB-231 cells ±SE (n = 3).
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Figure 3. Phosphorylation of LSD1 at serine-111 by PKC-θ regulates its pro-EMT function. (a) 
Immunofluorescence microscopy was performed on indicated cells fixed and probed with anti-LSD1, anti-
PKC-θ and DAPI. Representative images for each dataset are shown. Graph depicts the PCC for LSD1 and PKC-θ 
(n = 30 individual cells). −1 = inverse of colocalization; 0 = no colocalization; +1 = perfect colocalization. (b) 
Partial LSD1 amino acid sequence indicating the location of peptides positive for phosphorylation. Red amino 
acids = NLS region; blue amino acid = serine-111; green bars = location of peptides and are numbered in order 
of mean signal intensity. (c) Model of LSD1 generated using Phyre2, highlighting the close proximity of the 
serine-111 phosphorylation site to the positively charged NLS domain (inner box). LSD1 structure is based on 
PDB code 2V1D and cartoons were created in Pymol. (d) Partial LSD1 amino acid sequence indicating potential 
PKC-θ phosphorylation motifs near the NLS region (described in45). Red amino acids = NLS region; blue amino 
acids = potential PKC-θ phosphorylation sites. (e) LSD1-s111p TNFI in indicated cell lines (n > 30 individual 
cells). Representative images for each dataset are shown. (f) Graph indicates LSD1-s111p TNFI after treatment 
with vehicle alone, BIM or C27 as determined by immunofluorescence microscopy (n > 20 individual cells). (g) 
LSD1 H3K4 demethylation assay was performed on nuclear extracts from indicated cells after treatment with 
BIM, C27, or vehicle alone. Graph depicts percentage LSD1 demethylase activity relative to control (n = 2). 
(h) PCC for LSD1 and Snail after treatment with either BIM, C27, or vehicle alone (n ≥ 10 individual cells). 
−1 = inverse of colocalization; 0 = no colocalization; +1 = perfect colocalization. (i) LSD1-WT and LSD1-
Mut plasmid construct sequences. Blue amino acid = mutation site. (j) Graphs indicate LSD1-s111p TNFI, 
vimentin TCFI, and Snail TNFI after incubation with LSD1-WT, LSD1-Mut, or vector only as determined by 
immunofluorescence microscopy (n = 40 individual cells). Scale bars = 10 µM. All data represents the mean 
±SE. ns = p > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, Mann-Whitney test.
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phosphorylation has been identified45, so we also examined the relationship between phosphorylated peptides 
in the NLS region of LSD1 and identified PKC-θ motifs (Fig. 3d): the strongest peptide signals (peptides 1 and 2) 
contained three PKC-θ consensus phosphorylation motifs. Overall, these data suggest that nuclear PKC-θ directly 
phosphorylates LSD1 at multiple regions including the NLS region, most likely at serine-111.
We next investigated whether LSD1 serine-111 phosphorylation (LSD1-s111p) occurs in vivo during EMT. 
Immunofluorescence microscopy revealed that LSD1-s111p was entirely nuclear, and the LSD1-s111p TNFI sig-
nificantly increased in MCF-7/PMA + TGF-β and MDA-MB-231 cells relative to epithelial MCF-7 cells (Fig. 3e). 
On inhibiting PKC-θ with either C27 or BIM, the TNFI of LSD1-s111p was significantly reduced in all cell types 
except MCF-7 cells with BIM (Fig. 3f). This strongly indicates that PKC-θ is critical for phosphorylation of 
LSD1 at serine-111 and that this is important for nuclear localization. Inhibiting PKC-θ also increased the H3K4 
demethylase activity of LSD1 (Fig. 3g), indicating that active PKC-θ may prevent LSD1 from demethylating H3K4 
and subsequently causing gene repression. Moreover, PKC-θ inhibition with either agent significantly reduced 
LSD1 and Snail colocalization in both cells types (Fig. 3h).
To test the functional importance of serine-111 phosphorylation in EMT and CSCs, two plasmids were con-
structed: one expressing wild-type LSD1 (LSD1-WT) and the other containing a mutation at serine-111 to ala-
nine (LSD1-Mut) to prevent phosphorylation at this site (Fig. 3i). Transfection with LSD1-WT but not LSD1-Mut 
significantly increased LSD1-s111p, vimentin, and Snail expression in MCF-7 cells whereas transfection of 
MCF-7/PMA + TGF-β with the LSD1-Mut abrogated this induction (Fig. 3j). Collectively, PKC-θ can directly 
phosphorylate LSD1 at serine-111 to cause nuclear localization, which decreases the repressive activity of LSD1 
during EMT and regulates the expression of the EMT markers vimentin and Snail.
Co-binding of PKC-θ and LSD1 to the chromatin template promotes transcription during 
EMT. Since PKC-θ and LSD1 can both act as chromatin-anchored proteins, we were interested in determin-
ing whether they co-bound to chromatin in the mesenchymal state. Using our previously published MCF-7 
PKC-θ ChIP-seq data (MCF-7/PMA cells)38, we determined that of the 6487 regions bound by LSD1 (MCF-7/
PMA + TGF-β cells), 368 were enriched for PKC-θ (PCC = 0.04). However, when the regions were restricted 
to those within 1 kb of a TSS, the PCC increased to 0.14, and, when further restricted to those near a TSS of an 
inducible LSD1-sensitive gene, the PCC increased to 0.64. Furthermore, 63% of regions bound by both LSD1 
and PKC-θ were annotated as promoters/5′ UTR (Fig. 4a) and 84% had promoter marks in MCF-7 cells (Fig. 4b).
We next annotated each region bound by both LSD1 and PKC-θ to the nearest gene and overlaid this with 
MCF-7 and MCF-7/PMA + TGF-β LSD1 siRNA microarray data. 19% of the co-bound regions were annotated 
to genes that were inducible whilst 16% were annotated to genes whose expression was reduced in the presence of 
LSD1 siRNA in MCF-7/PMA + TGF-β cells. The percentages for regions bound by LSD1 only were significantly 
lower (p = 0.001 and 0.0001, respectively) (Fig. 4c). GO enrichment revealed that co-bound genes were enriched 
for several pathways and processes including: hippo, p53, TGF-β, and MAPK, as well as those for cell metabolism, 
gene regulation, and chromatin assembly.
Next, we profiled LSD1, PKC-θ, H3K4me3, and H3K27ac around the TSSs of LSD1-sensitive genes 
(Supplementary Fig. 5). LSD1 and PKC-θ binding increased at the TSSs between H3K4me3/H3K27ac (Fig. 4d, 
Supplementary Fig. 5) after EMT. Moreover, their binding appeared to target H3K4me3-high promoters, suggest-
ing that they might assist in transcribing these genes. Of the genes directly tethered by LSD1 and PKC-θ, several 
were EMT-TFs including JUNB, KLF10, and KLF6 in regions flanked by H3K4me3 and H3K27ac (Fig. 4e). Taken 
together, these data suggest that although PKC-θ and LSD1 predominantly occupy separate genomic compart-
ments, when they co-bind this occurs primarily at promoters and near a higher proportion of genes that are 
induced and are LSD1-sensitive. PKC-θ appears to promote LSD1’s role in transcriptional regulation.
LSD1 is involved in breast cancer growth and is enriched in chemoresistant cells. We were inter-
ested in understanding the impact of LSD1 expression on tumourigenicity and treatment resistance given: (i) the 
role that it plays in EMT and CSC regulation; and (ii) a CSC-phenotype is linked with resistance to chemotherapy 
and endocrine therapy6,46. LSD1 expression was first analyzed in a panel of luminal (SKBR3, MDA-MB-453, 
ZR751, MCF-7 and T47D) and basal B (MDA-MB-157, MDA-MB-436, MDA-MB-231, Hs578T and BT549) 
breast cancer cell lines47. LSD1 expression was higher in the less aggressive luminal cell lines than the aggressive 
basal B cell lines (Fig. 5a; full image shown in Supplementary Fig. 6). There was higher LSD1 expression in basal b 
cell lines (Fig. 5b) which are ER− and associated with poorer patient prognosis in clinical studies48. However, the 
repressive H3K4 demethylase activity of LSD1 is higher in luminal MCF-7 cells then basal B MDA-MB-231 cells 
(Fig. 1e). We speculate that while LSD1 levels are higher in luminal cancer cell lines it may have a more activatory 
role in aggressive basal B cancer cell lines. Using publicly available data, we found that LSD1 expression was higher 
in the breast cancers of patients who recurred after treatment than those who did not (GSE4913; Fig. 5c). Of the 
patients who recurred after treatment, LSD1 expression was higher in the primary carcinoma than the recur-
rent carcinoma (GSE4913; Fig. 5d). We further analyzed LSD1 levels in MCF-7, T47D and MDA-MB-231 cells 
that had developed resistance to docetaxel by stepwise exposure to the taxane (as described in49). Interestingly, 
we found that these cells were enriched in the stem-like marker, aldehyde dehydrogenase 1 family member A1 
(ALDH1A1) which is associated with both poor cancer prognosis and a CSC phenotype50, as well as PKC-θ 
and LSD1-s111p and moreover, there was increased colocalization between PKC-θ and LSD1-s111p (Fig. 5e). 
Collectively, these data suggest that LSD1 is involved in enriched in chemotherapy-resistance cells whereby it may 
facilitate tumour progression and recurrence.
This prompted us to examine the involvement of LSD1 in the growth of cancer xenografts in vivo. 
MDA-MB-231 cells were transplanted subcutaneously into the mammary fat pads of balb/c nude mice and 
treated with intraperitoneal (IP) injections of: (1) vehicle control only; (2) nab-paclitaxel (60, 30, or 10 mg/
kg); or (3) docetaxel (10 or 4 mg/kg) (details in Supplementary Fig. 7a). The tumour volume decreased in a 
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dose-dependent manner after treatments with both nab-paclitaxel and docetaxel with significant decreases in 
tumour volume observed after two weeks treatment in mice treated with the highest dosages (Fig. 5f,g). The 
surviving tumour cells were profiled for their expression of Snail and epidermal growth factor receptor (EGFR), 
which has been linked with tumour metastasis and treatment resistance51. On immunofluorescence staining, the 
surviving nab-paclitaxel-resistant tumour cells showed a significant increase in Snail and EGFR expression and 
docetaxel-resistant tumour cells showed a significant increase in Snail (Fig. 5h), consistent with a more aggressive 
phenotype. Further, after both treatments, there was a significant increase in LSD1 and LSD1-s111p expression 
(Fig. 5i), thus confirming that LSD1 is enriched in chemoresistant cells.
LSD1 inhibition in vivo suppresses tumour growth, chemotherapy-induced EMT, and CAFs. We 
next examined the effect of nab-paclitaxel and phenelzine – a well-characterised, LSD1 and monoamine oxidase 
inhibitor52 – alone or in combination on tumour growth and phenotype in vivo. Again, balb/c nude mice were 
injected subcutaneously into the mammary fat pads with MDA-MB-231 cells and treated by IP injections with: 
(1) vehicle only control; (2) nab-paclitaxel (30 mg/kg); (3) phenelzine (40 mg/kg); and nab-paclitaxel + phenelzine 
Figure 4. LSD1 and PKC-θ co-binding promotes transcription in mesenchymal cells. Diagram depicts 
proportion of peaks occupied by PKC-θ in MCF-7/PMA cells, LSD1 in MCF-7/PMA + TGF-β cells, and 
both PKC-θ and LSD1. LSD1 and PKC-θ ChIP-seq peaks and regions with both LSD1 and PKC-θ peaks were 
annotated to: (a) summarised chromatin environments of the nearest Ensembl transcript in different cell 
types. Peaks were classified as rRNA, 5’UTR, promoter (<1 kb from TSS), intergenic, intron, exon, pseudo, 
TTS, ncRNA or 3′UTR; and (b) summarised CTCF/chromatin states in MCF-7 cells. (c) Percentage of regions 
bound by LSD1 alone, both LSD1 and PKC-θ, or PKC-θ alone in the indicated gene groups where the number 
of regions is used as the denominator. (d) Average LSD1, PKC-θ, H3K4me3, and H3K27ac levels around the 
TSS of LSD1-sensitive genes. Reads are binned by 0.1 kb, ±1.5 kb around TSS. Dashed lines = MCF-7 samples; 
solid lines = MCF-7/PMA (PKC-θ) or MCF-7/PMA+ TGF-β (LSD1). (e) LSD1, PKC-θ, H3K4me3, H3K27ac, 
H3K9me3, and H3K27me3 ChIP-seq peaks at JUNB, KLF6, and KLF10 in indicated cell types as shown in the 
UCSC Genome Browser.
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(previously indicated concentrations) (details in Supplementary Fig. 7b). Five weeks post-treatment there was 
a significant reduction in nab-paclitaxel alone treated tumour volume and this was potentiated when adminis-
tered in combination with phenelzine treated mice (data not shown). We further validated these findings in the 
MDA-MB-231 balb/c nude mice model by treating with a combination of docetaxel (4 mg/kg) and pargyline, (100 
or 200 mg/kg) another LSD1 inhibitor. Similarly, we found a reduction in tumour volume as early as one week 
post-treatment with both high and low dosages of LSD1 inhibitor (Supplementary Fig. 8).
Figure 5. LSD1 is involved in breast cancer growth and is enriched in chemoresistant cells. (a) Western blots of 
indicated breast cancer cell line total cell extracts probed for LSD1. NPM and histone H3 were loading controls. 
Copped images are from samples and antibodies processed and run on the same gel. Full-length blot is shown in 
Supplementary Fig. 6. (b) LSD1 mRNA levels as measured by qPCR in breast cancer cell lines characterised as ER 
positive and ER negative. Data are expressed as arbitrary copy numbers normalised to PPIA (n = 2). LSD1 expression 
in: (c) local recurrent and non-recurrent breast carcinomas from GEO dataset GSE4913 (n ≥ 19); (d) primary 
and secondary locally recurrent breast carcinomas from GEO dataset GSE4913 (n ≥ 9); (e) Immunofluorescence 
microscopy was performed on matched parental and docetaxel-resistant MCF-7, T47D and MDA-MB-231 cells 
fixed and probed with anti-ALDH1A1, anti-PKC-θ and anti-LSD1-s111p. Graphs indicate ALDH1A, PKC- θ and 
LSD1-s111p TNFI and PKC and LSD1-s111p PCC (n = 20 individual cells). −1 = inverse of colocalization; 0 = no 
colocalization; +1 = perfect colocalization. (f) Tumour growth (mm3) up to 5 weeks post-treatment with indicated 
treatments (n = 5). Coloured asterisk (*) denotes significance at that time point. (g) Tumours sizes 5 weeks post-
treatment from left to right: control, nab-paclitaxel 60 mg/kg, nab-paclitaxel 30 mg/kg, nab-paclitaxel 10 mg/kg, 
docetaxel 10 mg/kg, and docetaxel 4 mg/kg. Tumours were excised and digested into single cell suspension and 
then subjected to immunofluorescence microscopy where TNFI was determined for control, nab-paclitaxel 60 mg/
kg, and docetaxel 10 mg/kg treated tumours after probing with: (h) anti-EGFR, anti-Snail; or (i) anti-LSD1, or 
anti-LSD1-s111p (n > 10). All data represents the mean ± SE. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 
Mann-Whitney test.
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Figure 6. LSD1 inhibition suppresses chemotherapy-induced EMT, CAFs and promotes a M1 macrophage 
infiltration. Balb/c nude mice were treated with either vector only, nab-paclitaxel 30 mg/kg, phenelzine 40 mg/
kg, or nab-paclitaxel 30 mg/kg + phenelzine 40 mg/kg. Tumours were excised, cut in half, digested with 
collagenase IV into single cell suspensions and immunofluorescence microscopy was performed on pooled 
samples and TNFI or TCFI was determined after probing with: (a) anti-LSD1, anti-LSD1-s111p; or (b) anti-
Snail, anti-EGFR, anti-CSV, anti-ABCB5, or anti-ALDH1A1 (n ≥ 15 individual cells from 5 pooled). (c) PCC 
was determined for FAP and LSD1 (n = 20 individual cells from 5 pooled). −1 = inverse of colocalization; 
0 = no colocalization; +1 = perfect colocalization. (d) Graphs indicate FAP TNFI and CCL2 TCFI (n = 20 
individual cells from 5 pooled). Representative image is shown for each data set. Scale bars = 10 µM. (e) 
Graph represents the total number of F4/80+ cells in individual tumours for each group as determined by 
flow cytometry (n ≥ 4). (f) TCFI of F4/80 (n = 60 individual cells from 5 pooled). Representative image is 
shown for each data set. Scale bars = 20 µM. (g) All cells were probed with anti-F4/80 and either anti-CCR7, 
anti-CD38, anti- CD206 or anti-EGR2. Cells that were determined to be F4/80-positive were then analyzed 
for their expression of M1- or M2-activated macrophage markers. TCFI was then determined for (h) CCR7, 
CD38; (i) CD206 and EGR2 (n ≥ 40 individual cells from 5 pooled). Black = control; red = nab-paclitaxel; 
blue = phenelzine; green = nab-paclitaxel + phenelzine. All data represents the mean ± SE. *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001, Mann-Whitney test.
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We next examined the expression of LSD1 and LSD1-s111p in the nab-paclitaxel and phenelzine alone and 
combination treated tumours. LSD1 and LSD1-s111p TNFI significantly increased in surviving nab-paclitaxel 
treated tumour cells and decreased significantly in tumour cells surviving phenelzine alone or combination 
treated tumour cells (Fig. 6a). Following this, we characterised the molecular phenotype of these tumours by 
examining the fluorescent intensity of several EMT, stem-like, and resistance markers, namely Snail, EGFR, 
cell-surface vimentin (CSV), ALDH1A and ATP-binding cassette sub-family B member 5 (ABCB5). CSV, 
ALDH1A and ABCB5 are all key markers of metastatic breast cancer (MBC) circulating tumour cells (CTCs). 
CTCs expressing CSV have been linked with poor prognosis in a variety of cancers53,54 whilst ALDH1A expres-
sion is linked with metastasis in solid tumours and early recurrence55,56. Similarly, ABCB5 has been linked with 
poor prognosis and multi-drug resistance57,58. Our data demonstrates that each of these markers increased after 
treatment with nab-paclitaxel alone but decreased after treatment with phenelzine or phenelzine in combination 
with nab-paclitaxel (Fig. 6b). Our data suggests that LSD1 and LSD1-s111p are upregulated in chemoresistant 
tumour cells and moreover, these cells appear to have undergone a chemotherapy-induced EMT and display an 
upregulation of mesenchymal and stem-like resistance markers. Targeting LSD1 in combination therapy block-
ades this in vivo chemotherapy-induced EMT and suppresses tumour growth.
Given the documented role of tumour stroma and in-particular CAFs in cancer progression, we were 
interested to see if inhibiting LSD1 affects CAFs in vivo. To investigate this further protein levels of the CAF 
markers, FAP and CCL2 as well as LSD1 were analyzed by immunofluorescence microscopy. While FAP is 
usually described as a soluble or membrane-bound protein, high-resolution microscopy suggested a potential 
nuclear role. FAP and LSD1 weakly colocalised in control samples but colocalization increased significantly in 
nab-paclitaxel alone treated samples and decreased significantly after treatment with phenelzine alone or combi-
nation treatments (Fig. 6c). There was also a significant increase in total fluorescence intensity of FAP and CCL2 
after nab-paclitaxel monotherapy that reduced significantly after LSD1 inhibition (Fig. 6d). These data indicate 
that CAFs increase in the tumour microenvironment after mono-chemotherapy but are reduced after LSD1 inhi-
bition alone or in combination with chemotherapy.
Given that LSD1 has recently been implicated in the regulation of monocyte-to-macrophage differentiation59 
and the lack of adaptive immunity in balb/c nude mice, we explored whether LSD1 may be modulating innate 
immunity through macrophage regulation. We found an overall decrease of F4/80+ cells by flow cytometry after 
all treatments indicating a reduction in macrophages (Fig. 6e). However, immunofluorescence microscopy indi-
cated that F4/80 TCFI increased significantly in combination treated samples (Fig. 6f). As these data indicate an 
infiltration of macrophages we were interested in determining if they were classical (M1) or alternatively activated 
(M2) macrophages. Immunofluorescence microscopy was performed probing for the M1 markers CCR7 and 
CD38 and the M2 markers CD206 and EGR2. To confirm that these markers were being expressed by mac-
rophages, cells were first screened for the presence of F4/80 staining and subsequently for co-expression of M1 or 
M2 markers (Fig. 6g). There was a significant increase in M1-associated CCR7 and CD38 after phenelzine alone 
and combination treatments (Fig. 6h). Conversely, there was a significant decrease in M2-associated CD206 and 
EGR2 after all treatments (Fig. 6i). Finally, haematoxylin and eosin staining of control, docetaxel-treated, and 
combined pargyline-docetaxel-treated tumours revealed an infiltrating front of immune cells at the periphery 
of the carcinomas after combination treatment that was less apparent in chemotherapy alone treated or control 
samples (Supplementary Fig. 9).
Taken together, these data demonstrate that LSD1 induces upregulation of a mesenchymal, stem-like, and 
resistance signature in cancer cells that survive chemotherapy. Combination treatment with a LSD1 inhibitor 
is advantageous as both the bulk tumour cell population and the mesenchymal, stem-like, resistance signature 
are significantly abrogated along with a reduction in CAF signature and increased M1 macrophage and innate 
immune cell infiltration potentially supporting the role of LSD1 in reducing recurrence.
LSD1 is upregulated in CTCs isolated from MBC patient liquid biopsies and is associated with 
a mesenchymal- and CSC-like phenotype. Given that our results thus far strongly suggest that LSD1 is 
involved in a multitude of breast cancer programs, we investigated the role of LSD1 in promoting mesenchymal 
and CSC-like CTCs from patients with Stage IV MBC. CTCs are a crucial component of the metastatic cascade, 
tumour dissemination, progression and tumour recurrence/relapse. The study recruited 10 patients classified 
as having stage IV MBC who at baseline were ER+/PR+/HER2− and had received any form of systemic therapy. 
CTCs from liquid biopsies were identified using the DEPArray based on high expression levels of vimentin, 
cytokeratin (CK) and the absence CD45 expression (Fig. 7a). CD45−/VIM+/CK+ CTCs were counted and then 
isolated from all patients at two time points, six weeks apart during standard of care (sample 1 and sample 2, 
respectively) (Fig. 7b). All MBC patient liquid biopsies contained CTCs, in contrast, no CTCs were detected from 
healthy donors (Fig. 7c).
We characterised isolated CTCs to determine if they expressed markers indicating a mesenchymal pheno-
type. High resolution fluorescent microscopy demonstrated that the MBC CTCs could be separated into three 
distinct groups based on their expression of LSD1-s111p or LSD1. Examining the co-expression of LSD1-s111p, 
Snail and CSV revealed that cells expressing high levels of LSD1-s111p (TNFI >1100; denoted phenotype 1) 
also expressed high levels of Snail and CSV. Whilst phenotypes 2 and 3 which expressed moderate (TNFI 500–
1100) and low (TNFI <500) levels of LSD1-s111p, had moderate and low levels of EMT markers, Snail and CSV, 
respectively, demonstrating that LSD1-s111p levels are proportional to the mesenchymal status of CTCs (Fig. 7d). 
Interestingly, phenotype 1 cells comprised the bulk of the MBC CTCs (76%), while 14% where phenotype 2 and 
10% were phenotype 3 (Fig. 7e). To further investigate the co-expression signature of these CTCs we examined 
a panel of stem like-resistant biomarkers including ALDH1A and ABCB5 in the context of LSD1 expression50,60. 
Similarly, we determined that within this panel, phenotype 1 comprised 71% of the CTCs and co-expressed 
high levels of LSD1 (TNFI >1500) and the stem-like markers, ALDH1A and ABCB5. Phenotype 2 (19%) and 
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Figure 7. LSD1 correlates with MBC CTC mesenchymal- and CSC-like characteristics. (a) CTCs were isolated 
from MBC patient liquid biopsies through double expression of cytokeratin (CK) and vimentin (VIM) and 
absence of CD45 expression on the DEPArray. Representative image from DEPArray and workflow shown. 
(b) CD45−/VIM+/CK+ CTC cell counts were determined in two samples collected six weeks apart (sample 1 
and sample 2, respectively) (n = 10). (c) Immunofluorescence microscopy was performed on all fixed CTCs 
collected from 10 MBC patients at each time point and compared to normal donors. Representative images 
showing DAPI staining in CTCs is shown (n = 5 healthy donors and 10 MBC patients). (d) CTCs were 
separated based on LSD1-s111p TNFI relative to negative controls, primary and secondary antibody controls as 
well as healthy donor expression into phenotypes 1, 2 and 3 (high, moderate and low expression, respectively) 
and Snail TNFI and CSV TCFI were determined (n = 10). Representative images are shown for each dataset. 
(e) Average percentage of phenotype 1, 2 and 3 cells (n = 10). (f) CTCs were separated based on LSD1 TNFI 
relative to negative controls, primary and secondary antibody controls as well as healthy donor expression 
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phenotype 3 (10%) CTCs expressed moderate (TNFI 600–1500) and low (TNFI <600) levels of LSD1 correlating 
ALDH1A and ABCB5 expression (Fig. 7f,g). Moreover, LSD1 strongly colocalised with ALDH1A (Fig. 7h).
Next, we investigated whether LSD1-s111p and CSV along with CTC count was altered with MBC disease 
progression. Thus, we tracked the fluorescent intensity of these markers and CTC count in one patient at numer-
ous time points. Standard of care monitoring (CT scans (RECIST 1.1), blood work, clinical symptoms/judge-
ment) indicated that progression of metastatic disease and increasing disease burden was accompanied by an 
increase in CTC count in this patient. Intriguingly, there was a spike in the co-expression of both LSD1-s111p and 
CSV that preceded the substantial increase in CTC count (indicated by arrows) (Fig. 7i).
To further investigate the role of LSD1 in CTC regulation, we treated isolated MBC patient CTCs with vehicle 
alone, pargyline or phenelzine and monitored the expression of mesenchymal protein biomarkers. Inhibition 
of LSD1 significantly reduced the fluorescent intensity of CSV, Snail and LSD1-s111p after both pargyline and 
phenelzine treatment (Fig. 7j and k, respectively). Additionally, treatment with either pargyline or phenelzine 
significantly reduced the TNFI of the CSC marker, ALDH1A (Fig. 7l). Similarly, we found significant reductions 
in VIM and CD44 mRNA transcript levels by qPCR (Fig. 7m). Overall, these results demonstrate that LSD1 has 
a role in promoting both the mesenchymal and CSC signature of MBC CTCs. Abrogation of LSD1 mediates a 
reduction of CSC burden whilst reducing the mesenchymal status suggesting that LSD1 maybe be a critical target 
in lessening the CSC and disease burden in MBC patients.
Discussion
In response to inflammatory signal-mediated EMT, LSD1 expression was induced, subsequently peaked, and then 
returned to baseline upon complete dedifferentiation. Although LSD1 mRNA levels reverted to baseline, LSD1 
protein persisted and colocalised with the key EMT-TF Snail during EMT and regulated the expression of several 
EMT markers including Snail, vimentin, and E-cadherin. These findings are consistent with previous reports that 
LSD1 regulates transcription of EMT pathways in breast cancer22,29. However, the molecular mechanisms through 
which LSD1 regulates EMT and other aspects of cancer progression is only beginning to be elucidated.
In the present study, we have demonstrated that LSD1 regulated widespread genomic changes during EMT 
that result in active induction of CSC phenotype mediated by increased expression of multiple EMT-related 
genes. Of the genes that were LSD1-sensitive, the majority were induced rather than repressed during EMT. 
This is consistent with the decrease in repressive LSD1-mediated H3K4 demethylase activity we observed in 
mesenchymal-like cells. Importantly, of the induced LSD1-sensitive genes, many were EMT related including 
the regulation of cell migration, motility, and differentiation2 and EMT pathways such as TGF-β and PI3K-Akt 
signaling61.
We found that upon induction of EMT, LSD1 occupancy shifted from preferentially binding at intergenic and 
intronic regions to binding a larger proportion of promoter regions. Moreover, LSD1 binding increased at regions 
annotated as active promoters and reduced in those annotated as repressed chromatin in MCF-7 cells40. These 
findings differ from those in embryonic stem cells (ESC), in which LSD1 largely lies on the enhancers of actively 
transcribed and bivalent genes62; indicating that LSD1 binding is likely to be cell type specific. Although we found 
that LSD1 induced a large number of genes, around 86% of these were not tethered by LSD1. LSD1 did, how-
ever, directly regulate the expression of several EMT-TFs including JUNB, KLF10, and KLF6, probably indirectly 
through the action of directly targeted LSD1-sensitive TFs.
This study demonstrates for the first time that PKC-θ interacts with LSD1 during breast cancer EMT, with 
LSD1 and PKC-θ colocalizing in mesenchymal-like cells but not in epithelial cells. At the chromatin level, PKC-θ 
and LSD1 bound separate genomic regions in MCF-7 cells, however, in cells that have undergone EMT both 
proteins predominantly co-occupied promoter regions of genes induced during EMT in a LSD1-dependent man-
ner. Indeed, our data indicated that LSD1 and PKC-θ co-binding occurred between H3K4me3 and H3K27ac 
flanked regions, targeted H3K4me3 rich promoters, and occurred predominantly at induced LSD1-sensitive 
genes. Previously, PKC-β has been shown to colocalise with LSD1 and the androgen receptor (AR) at target gene 
promoters, where PKC-β mediates H3T6 phosphorylation to facilitate gene expression63. We propose that a sim-
ilar mechanism occurs during breast cancer EMT, with PKC-θ occupying select promoter regions with LSD1 and 
acting to enhance LSD1-mediated gene induction in response to inflammatory signal-induced EMT.
We exploited peptide microarray kinase profiling to show that PKC-θ directly phosphorylates LSD1 at mul-
tiple sites. Several of these regions were within the NLS of LSD1, especially serine-111, whose phosphorylation 
was (i) dependent on PKC-θ activity and (ii) increased in the nucleus to facilitate vimentin and Snail induction in 
mesenchymal-like cells. Moreover, PKC-θ inhibition increased repressive LSD1 H3K4 demethylase activity, indi-
cating that PKC-θ normally reduces LSD1-mediated repression. In in vivo mice models, PKC-α has been shown 
into phenotypes 1, 2 and 3 (high, moderate and low expression, respectively) and ALDH1A TNFI and ABCB5 
TNFI were determined (n = 10). Representative image is shown for each dataset. (g) Average percentage of 
phenotype 1, 2 and 3 cells (n = 10). (h) Graph depicts the PCC for LSD1 and ALDH1A (n = 10). −1 = inverse 
of colocalization; 0 = no colocalization; +1 = perfect colocalization. (i) Graph depicts LSD1-s111p TNFI, CSV 
TCFI and CD45−/VIM+/CK+ CTC cell count in five samples collected at indicated time points. Representative 
images are shown for each time point (n = 1 patient). Isolated CTCs were treated with either vehicle alone, 
pargyline or phenelzine and then immunofluorescence microscopy or qPCR was performed. Total florescence 
intensity of CSV and LSD1-s111p and Snail after treatment with (j) pargyline; or (k) phenelzine (n > 75 cells 
from 10 patients). (l) ALDH1 TNFI after treatment with pargyline or phenelzine (n = 20 cells from 10 patients). 
(m) VIM and CD44 mRNA transcript levels after treatment with pargyline or phenelzine (n = 10 pooled). Scale 
bars = 10 μM. ns = p > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, Mann-Whitney test.
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to phosphorylate mouse LSD1 at serine-112 (analogous to serine-111 in humans) in a cardiac rhythm-dependent 
manner and in breast cancer EMT and metastasis to enable E-box-mediated transcription64,65. Here we show 
for the first time that PKC-θ directly phosphorylates LSD1 and facilitates breast cancer EMT. Recent work has 
shown that the histone acetyltransferase, MOF, acetylates LSD1 at lysine residues 432, 433 and 436 in epithelial 
cells thereby displacing LSD1-chromatin interactions and suppressing EMT66. We speculate that a reduction in 
MOF levels precedes EMT, followed by phosphorylation of LSD1 at serine-111 by PKC-θ thus facilitating EMT 
by allowing LSD1 translocation to the nucleus, chromatin docking and subsequent demethylation of target genes.
We found that in vivo, chemotherapy was sufficient to reduce the primary tumour bulk, however, our data 
strongly suggests that LSD1 participates in the malignant phenotype and that its inhibition in combination with 
chemotherapy further suppresses tumour growth. LSD1-s111p was enriched in chemoresistant mesenchymal 
tumour cells after cytotoxic monotherapy, where it may play a role in chemotherapeutic resistance as suggested 
by our data demonstrating an increase in EGFR, ALDH1A and ABCB5 in these cells. Moreover, targeting LSD1 
significantly reduced features of EMT and a stem-like resistance signature that were induced after chemotherapy, 
as well as the expression of both LSD1 and its phosphorylated form. These results are consistent with findings that 
LSD1 modifies the chemosensitivity of mouse hepatocytes undergoing TGF-β-induced EMT23.
Our in vitro data indicated that LSD1 selectively induces CSC genes whilst repressing NCSC subsets to pro-
mote cancer progression. Aside from regulating transcription in these cells, our results suggest that LSD1 may 
also regulate CSCs indirectly through the action of CAFs. LSD1 colocalised with the activated CAF marker, FAP, 
after nab-paclitaxel monotherapy, and targeting LSD1 in a combination therapy reduced CAF markers that were 
induced by the chemotherapy alone. Given the CAFs are implicated in regulating CSC self-renewal through para-
crine mechanisms via increased secretion of cytokine CCL235, LSD1 may also regulate breast CSC self-renewal by 
modulating the tumour microenvironment. Moreover, our data strongly suggests that LSD1 represses the innate 
immune response by regulating macrophage infiltration to the primary tumour site. Recent work has suggested 
that LSD1 may be involved in repressing monocyte-to-macrophage differentiation after THP-1 treatment poten-
tially via H3K4 methylation at target gene promoters59. It is possible that a similar mechanism is in play here.
Data acquired from isolated CTCs from liquid biopsies of 10 MBC patients revealed that LSD1 is enriched in 
CTCs with mesenchymal, stem-like phenotypes. LSD1 expression increases during breast cancer progression and 
precedes detectable changes in CTC load, suggesting that LSD1 expression may be a predictive marker of disease 
prognosis. We found that LSD1 colocalises with stem-like markers in CTCs and pharmacological inhibition of 
LSD1 reduces the CSC- and mesenchymal-like phenotype of these cells. This suggests that not only may LSD1 be 
a predictive biomarker, it may regulate the metastatic properties of CTCs thereby regulating tumour progression. 
However, one limitation of our study is the small numbers of CTCs that can be recovered with current technol-
ogies, which in turn limits the scope and breadth of detailed epigenetic analysis at the individual patient level. 
As these CTC recovery and epigenetic based technologies improve for primary cell work this shortfall of cell 
numbers can be addressed allowing for more detailed epigenetic analysis. Additionally, whilst outside the pur-
view of this study, it is of importance to investigate how multiple variables including cancer stage (Stage I to IV), 
hormonal status and therapy received each influence the expression of LSD1 in CTCs from patients with MBC.
We therefore propose a model in which LSD1 expression is transiently increased due to inflammatory signals 
induced at the primary tumour site. A global increase in LSD1 levels (Fig. 1b) coincides with a shift in LSD1 
binding to promoter regions (Fig. 2c,d) and subsequently, LSD1 initiates genomic programs that promote EMT 
(Fig. 2b). Moreover, LSD1 selectively induces gene expression in a subpopulation of CSCs (Fig. 2i) and due to the 
chemoresistant nature of such CSCs, LSD1 is overrepresented after chemotherapy (Fig. 5e,i,a). LSD1 promotes 
other aspects of tumour progression by increasing CAFs (Fig. 6d), and repressing a M1 macrophage immune 
infiltrate at the primary tumour site (Fig. 6h). Additionally, LSD1 promotes the expression of mesenchymal char-
acteristics of CTCs that have shed from the primary tumour into the circulatory system (Fig. 7j–m). However, 
whilst our in vitro data suggests that an increase in LSD1 occurs in response to increased inflammatory signalling 
(Fig. 1a,b), further experiments will be needed to validate that this occurs at the primary tumour site. Such studies 
should examine the correlation between key pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α and 
LSD1 levels.
Here we explored the role of LSD1 in breast cancer EMT, CSCs, and therapeutic resistance. We showed that 
LSD1 is reversibly induced during EMT where it regulates inducible EMT-related gene expression programs, 
primarily by PKC-θ-mediated phosphorylation of LSD1 at serine-111. In vivo, LSD1 inhibition in combination 
with chemotherapy represses tumour growth by inhibiting the mesenchymal, CAF and CSC phenotypes that were 
induced by chemotherapy alone. Additionally, combined inhibition increased innate immunity by regulating 
macrophage infiltration. Overall, our findings suggest that altering the LSD1 landscape can prime cancers, the 
stromal microenvironment, and immune cells for optimal chemotherapeutic action.
Establishing exactly how LSD1 regulates cell fate in the face of chemotherapy will potentially facilitate the 
development of epigenetic therapies that specifically target these mechanisms. Epigenetic therapies are prime 
candidates for adjuvant treatment with either chemotherapy or immunotherapy. Thus, understanding how LSD1 
and LSD1-s111p differentially regulate such processes is paramount in selecting and designing effective treatment 
regimes. Current clinical trials in this space utilizing epigenetic drugs in combination therapy are showing prom-
ise in treating metastatic cancers67. In this context and in light of our findings, a phase 1 clinical trial would be 
most efficacious by combining a selective LSD1 inhibitor or PKC-θ inhibitor – to prevent serine-111 phosphoryl-
ation – with standard of care for patients with MBC. Such combination therapeutic strategy would likely improve 
patient survival by targeting the specific form of LSD1 modulating the tumour microenvironment to impede not 
only tumour burden but recurrence resulting in a favorable anti-tumour environment.
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Methods
Cell culture. All breast cancer cell lines used were sourced from ATCC, except the docetaxel resistant lines 
which were kind gift of Dr Sikic (Standford University). Cell lines were maintained and cultured in DMEM 
(Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, and 1% PSN. MCF-7 cells were stimulated with 
1.29 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) and 5 ng/ml recombinant TGF-β1 (R&D 
Systems) for 60 hours38. For inhibitor experiments, 10 µM, 1 µM and 0.1 µM erlotinib (Roche), 3 mM pargyline 
(Sigma-Aldrich), 500 µM phenelzine (Sigma-Aldrich), 1 µM BIM (Calbiochem), and 1 µM C27 (SYNthesis Med 
Chem) were used. All inhibitors were pre-incubated for 24 hours before stimulating cells. Forward transfec-
tion reactions were performed with 40 nM human siRNA (sc-60970) and mock siRNA (sc-36869) (Santa Cruz 
Biotechnology) using Lipofectamine 2000 (Invitrogen). Vector transfections were performed with 15 µg of either 
vector only plasmid (pTracer-CMV/BSD, Thermo Scientific), LSD1-WT, or LSD1-Mut (Serine-111 to Alanine) 
using the NEONTM Transfection System kit (MPK5000; Invitrogen).
RNA extraction and quantitative real-time PCR. Total RNA was extracted from cells as previ-
ously described68. 1 μg of extracted RNA was subsequently treated with recombinant DNase I (Roche) and 
reverse-transcribed using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) according to the 
manufacturer’s protocol. TaqMan quantitative real-time PCR was performed as previously described68. Human 
TaqMan probes utilised were: LSD1 (Hs01002741_m1), CDH1 (Hs00170423_m1), VIM (Hs00958111_m1), 
SNAI1 (Hs00195591_m1), CD44 (Hs01075861_m1), and PPIA (Hs99999904_m1).
Immunofluorescence microscopy. Immunofluorescence microscopy was performed to determine the 
TNFI, TCFI and PCC as previously described69,70. PCC values were determined by the strength of the relation-
ship between two fluorochrome signals. Primary antibodies were: anti-rabbit-LSD1 (05–939; Merck Millipore), 
anti-goat-SNAI1 (sc-10433; Santa Cruz), anti-mouse-E-cadherin (sc-21791; Santa Cruz), anti-mouse-vimentin 
(sc-6260; Santa Cruz), anti-rabbit-PKC-θ-T538p (ab63365; Abcam), anti-rabbit-LSD1-s111p (ABE1462; Merck 
Millipore), anti-rabbit-ALDH1A1 (ab52492; Abcam), anti-rabbit-EGFR (ab2430; Abcam), anti-mouse-CSV 
(H00007431-M08; Abnova), anti-goat-ABCB5 (ab77549; Abcam), anti-rabbit-FAP-α (ab28244; Abcam), 
anti-goat CCL2 (sc-1304; Santa Cruz), anti-goat-F4/80 (sc-26642; Santa Cruz), anti-goat-CCR7 (NB100–
712; Novus Biologicals), anti-mouse-CD38 (102761; Biolegend), anti-mouse-CD206 (ab8918; Abcam), and 
anti-goat-EGR2 (sc-204050; Santa Cruz). Secondary antibodies used: anti-rabbit-Alexa Fluor 488 (A21206; Life 
Technologies) or anti-rabbit-Alexa Fluor 568 (A10042; Life Technologies), anti-mouse-Alexa Fluor 568 (A10042; 
Life Technologies), or anti-goat-Alexa Fluor 633 (A21082; Life Technologies).
LSD1 activity assay. LSD1 H3K4 Demethylation Activity Assay (KA1525, Abnova) was performed on 
nuclear extracts from MCF-7 and MDA-MB-231 cells in duplicate wells according to the manufacturer’s protocol.
Flow cytometry. Flow cytometry and the CSC gating strategy were performed as in38. Briefly, cells were 
stained with anti-CD44-APC (559942; BD Biosciences), anti-CD24-PE (555428; BD Biosciences) antibodies, and 
Hoechst 33258 (94403; Sigma-Aldrich). Flow cytometry acquisition was performed on single cell suspensions 
using BLSR II. Analysis was performed using FlowJo software.
Western blotting. Western blot analysis of total cell extracts from breast cancer cell lines was performed 
using primary anti-rabbit-LSD1 (ab17721; Abcam), anti-histone H3 (4499; CST), and anti-NPM (3542 S; CST) 
and secondary HRP-conjugated-anti-rabbit (A0545; Sigma-Aldrich). Signals were detected by the Super Signal 
Chemiluminescent ECL-plus (Amersham) with film exposure.
Microarray analysis. Microarray studies were performed on MCF-7 and MCF-7/PMA + TGF-β cells treated 
with either mock or LSD1 siRNA. Hugene 2.0 ST arrays were normalised using RMA in Affy Power Tools 1.16.1. 
Only probes annotated as ‘main’ were used. Probe sets were called differentially expressed if greater than log2 0.5 
different.
ChIP and ChIP-seq. ChIP was performed as previously described38 with 10 μg of anti-LSD1 (ab17721; 
Abcam). A no antibody IP control and total input control were included to ensure specific enrichment compared 
to total genomic DNA. The quality of ChIP DNA was assessed on a 2100 Bioanalyzer (Agilent). ChIP librar-
ies were prepared with 10 ng of ChIP DNA using the TruSeq® ChIP Sample Preparation Kit (Illumina) at the 
Ramaciotti Centre for Gene Function Analysis, University of New South Wales, Sydney. ChIP DNA libraries were 
then sequenced on the Illumina NextSeq. 500 using a 75 bp high output single-read run.
ChIP-seq analysis. Reads were adapter stripped (CutAdapt), mapped to Hg19 (bowtie2), and duplicates 
removed (Picard). BedGraph files were created from the first read using HTSEQ. Enriched regions were called 
against Total Input with the first read of the pair using HOMER (-fragLength 200 findPeaks -style histone -F 4 
-size 300 -minDist 300) and then filtered so that each region had at least 12.2 normalised reads. HOMER was 
used to annotate and profile the regions, search for enriched motifs and ontology, count tags in the regions, and 
profile histone and other marks. HOMER was also used to peak call enriched PKC-θ regions from previously pub-
lished PKC-θ ChIP-seq data38. Overlapping peaks were defined as those with any overlap. PCCs of binding were 
determined using the tag counts in merged regions from PKC-θ and LSD1 standardised to 300 bp. R was used 
to determine if the center of the regions occurred within given distances to gene transcription start sites (TSSs; 
obtained from Affymetrix annotation file na.35). Microarray expression and ChIP-seq data are deposited in the 
Gene Expression Omnibus (GEO) under accession number GSE104755.
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Kinase profiling on peptide microarrays. Active recombinant PKC-θ was provided to JPT Peptide 
Technologies (Berlin, Germany) for kinase profiling on peptide microarrays. Unmodified LSD1 peptides were 
chemoselectively immobilised on glass slides and incubated with kinase solution in the presence of g-³³P-ATP 
prior to high-resolution phosphorimaging. GenepixPro 7.2 and ArrayPro 4.0 spot recognition software packages 
were used for data acquisition and analysis. Peptide constructs that displayed a normalised mean signal equal to 
or greater than 2 SDs above the mean were considered positive for phosphorylation events. Excel, R, and Python 
were used to determine the statistical significance of sequences and phosphorylation events.
MDA-MB-231 mouse xenografts. Five-week-old female nude mice were acquired from the Animal 
Resources Centre (Perth) and allowed to acclimatize for one week in the animal facility at the John Curtin 
School of Medical Research (JCSMR) before experimentation. All experimental procedures were performed in 
accordance with the guidelines and regulations accessed and approved by The Australian National University 
Animal Experimental Ethics Committee (Ethics ID A2014/30). MDA-MB-231 human breast carcinoma cells 
were injected subcutaneously into the right mammary gland (2 × 106 cells in 1:1 PBS and BD Matrigel Matrix). 
Tumours were measured using external calipers and calculated using the modified ellipsoidal formula: ½ (a/b2), 
where a = longest diameter and b = shortest diameter. Tumours were allowed to grow to around 50 mm3 before 
commencing treatments (around 15 days). All treatments were given by IP injections. Tumours were excised and 
collected in DMEM supplemented with 2.5% FCS. Tumours were then finely minced using a surgical blade and 
incubated at 37 °C for 1 hour in DMEM 2.5% FCS and collagenase type 4 (Worthington-Biochem) (1 mg of col-
lagenase/1 g of tumour). Digested tumours were spun and resuspended in DMEM 2.5% FCS before being passed 
through a 0.2 µM filter and used for fluorescence microscopy as described earlier.
Isolation of circulating tumour cells. Liquid biopsies were collected from 10 patients with ER+/PR+/
HER2− Stage IV MBC and had received any form of systemic therapy. Disease burden was assessed by stand-
ard of care monitoring (CT scans (RECIST 1.1), blood work, clinical symptoms/judgement). Liquid biopsies 
were pre-enriched using the RosetteSep™ method to isolate CTCs by employing the RosetteSep™ Human 
CD45 Depletion Kit (15162, Stemcell Technologies) to remove CD45+ cells and red blood cells, using density 
gradient centrifugation with SepMate™-15 (IVD) density gradient tubes (85420, Stemcell Technologies) and 
Lymphoprep™ density gradient medium (07861, Stemcell Technologies). Enriched CTC samples were then quan-
tified on the DEPArray™ single cell isolation system using the manufacture’s protocol. Samples were stained 
with anti-APC-CD45 (555485; BD Biosciences), anti-FITC-pan-cytokeratin (130-080-101; Miltenyi Biotec) and 
anti-PE-vimentin (562337; BD Biosciences) to confirm the presence of CTCs and produce a CTC count per 7.5 ml 
of blood. Only CD45−/Cytokeratin+/Vimentin+/DAPI+ cells were considered as CTCs. Purified CTC samples 
were then either left untreated or treated with either 3 mM pargyline or 500 µM phenelzine for 12 hours and then 
processed for high resolution immunofluorescence through methods described earlier. All experimental proce-
dures relating to human studies were performed in accordance with the guidelines and regulations approved by 
the ACT Health Research Ethics and Governance Office: Human Research Ethics Committee, Building 10, The 
Canberra Hospital, Garran, ACT, 2605 (Ethics ID ETH.11.15.217). Written informed consent was received from 
all patients prior to inclusion in the study.
Statistics. All comparisons between samples were evaluated using the two-tailed non-parametric 
Mann-Whitney test (GraphPad Prism) unless otherwise stated in figure legends. Where applicable, statistical 
significance is denoted by * for P ≤ 0.05, ** for P ≤ 0.01, *** for P ≤ 0.001, and **** for P ≤ 0.0001. Data are 
expressed as mean ± SE.
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